Related Experiment Videos
Global regulatory considerations for unified assay specifications
S Patterson1, L Lin, J Elchico
1Chiron Corporation, Emeryville, CA, USA.
Developments in Biological Standardization
|January 1, 1997
Summary
Global biotechnology product registration requires unifying specifications across regions like the US, Europe, and Japan. Differences in regulatory guidelines, pharmacopoeias, and analytical methods present challenges, as seen with Betaseron (interferon beta-1b) registration.
Area of Science:
- Biotechnology
- Regulatory Affairs
- Pharmaceutical Science
Background:
- Global drug development necessitates harmonizing product specifications for international registration.
- Discrepancies exist in regulatory guidelines, pharmacopoeias, and analytical testing methods across the United States, Europe, Japan, and Rest-of-World (ROW) countries.
- Evolving analytical techniques can introduce new testing requirements during product development.
Purpose of the Study:
- To evaluate aspects of unifying specifications for biotechnology products during global registration.
- To identify challenges and successes in harmonizing regulatory requirements and testing methods.
- To illustrate the complexities using the Betaseron (interferon beta-1b) global registration process as a case study.
Main Methods:
- Comparative analysis of regulatory guidelines and pharmacopoeial requirements in key global markets (US, Europe, Japan, ROW).
- Assessment of state-of-the-art analytical methods and their impact on product testing specifications.
- Examination of the Betaseron (interferon beta-1b) registration dossier and approval process to identify unification successes and failures.
Main Results:
- Significant variations were observed in regulatory guidelines and pharmacopoeial testing methods for sterility, safety, and pyrogenicity across different regions.
- The dynamic nature of analytical science led to the incorporation of new tests into release specifications during the development lifecycle.
- The Betaseron case study highlighted specific instances where specification unification was achieved and areas where divergence persisted.
Conclusions:
- Unifying global specifications for biotechnology products is complex due to regional regulatory and pharmacopoeial differences.
- Adaptability to evolving analytical methods is crucial, but can also complicate harmonization efforts.
- Strategic evaluation of regional requirements and the Betaseron experience offer insights for future global drug registration strategies.